RecruitingPhase 1NCT06752486

Assessment of Safety and Efficacy of Gabapentin After Surface Ablation, a Case Control Experimental Study

Assessment of Safety and Efficacy of Gabapentin for Postoperative Analgesia After Surface Ablation, Versus Diclofenac Potassium as a Gold Standard

Sponsor

Research Institute of Ophthalmology, Egypt

Enrollment

64 participants

Start Date

Dec 1, 2024

Study Type

INTERVENTIONAL

Conditions

Pain After Photorefractive Keratectomy VAS Will be Used to Assess Pain Postoperative

Summary

The current study aims at assessing the efficacy and safety of oral Gabapentin alone versus Diclofenac Potassium drugs for postoperative analgesia in patients undergoing surface ablation.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Giving post photorefractive keratectomy for pain relief for people with pain after photorefractive keratectomy and vas will be used to assess pain postoperative. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGiving post photorefractive keratectomy for pain relief

We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.

Locations(1)

Research Institute of Ophthalmolgy

Giza, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06752486